Company: AKO-B
Filing Date: 2025-05-07
Form Type: 6-K
Source: 0001104659-25-045391
Chunk: 74

Company: ANDINA BOTTLING CO INC
Filing Date: 2025-05-07
Form: 6-K
Chunk 74
---
 types of risk
caused by exchange rate volatility in the countries where it operates:

a) Exposure of foreign investment

This risk originates from the translation of net
investment from the functional currency of each country (Brazilian Real, Paraguayan Guaraní, and Argentine Peso) to the Parent
Company’s reporting currency (Chilean Peso). Appreciation or devaluation of the Chilean Peso with respect to the functional currencies
of each country, originates decreases and increases in equity, respectively. The Company does not hedge this risk.

The Company evaluates the fluctuations of the currencies used in the
Operations (local currencies) with respect to the presentation currency of the financial statements through a sensitivity analysis on
total assets, total liabilities and net equity in local currency.

|                                                              |     | USD/CLP |      |   |     | BRL/CLP |     |   |     | ARS/CLP |      |   |     | PGY/CLP |      |   |
| Real                                                         
 closing exchange rate variation March 2025 vs. December 2024 |     |         | -4,4 | % |     |         | 3,1 | % |     |         | -8,1 | % |     |         | -6,3 | % |

|                   |     |      Brazil |   |     |   Argentina |   |     |    Paraguay |   |
|                   |     |       ThCh$ |   |     |       ThCh$ |   |     |       ThCh$ |   |
| Total assets      |     | 941,864,114 |   |     | 523,615,156 |   |     | 368,840,600 |   |
| Total liabilities |     | 575,768,551 |   |     | 180,275,679 |   |     |  62,159,330 |   |
| Net investment    |     | 366,095,563 |   |     | 343,339,477 |   |     | 306,681,270 |   |
| Share on income   |     |        26.5 | % |     |        26.3 | % |     |         8.7 | % |

|                                                             |     | BRL/CLP |   |     | ARS/CLP |   |     | PGY/CLP |   |
| Impact